A 14-gene, quantitative-polymerase chain reaction-based assay appears to reliably identify patients with early-stage non-small-cell lung cancer (NSCLC) who are at high risk for mortality after surgical resection. The assay was designed to improve risk stratification in patients with non-squamous NSCLC.
Abstract: Lancet, January 27, 2012.
